Drug Trial Radar · NCT02947867
Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG
Last checked: Nov 19, 2026Latest source record: Oct 31, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
333
Planned (sponsor's estimate)
Start
Jan 2017
Primary completion
Jun 2019
Study completion Dec 2019
Sponsor
- Lead sponsor
- Gene Signal SASIndustry
- Sponsor type
- Industry
- Collaborators
- Johannes Gutenberg University Mainz; University Hospital of Cologne; Moorfields Eye Hospital NHS Foundation Trust
- First posted
- Oct 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, randomised, placebo-controlled, double-masked, three-armed multi-centre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG Study
Conditions
- Ischaemic Central Retinal Vein Occlusion
- Neovascular Glaucoma
Interventions
aganirsenDrug
aganirsen antisense oligonucleotide against Insulin Receptor Substrate (IRS-1)
Primary outcomes
What the sponsor says the trial is designed to measure.
- NVG componentTime frame: Week 24
- IOP componentTime frame: Week 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.